4
Changes in Ownership
Cartesian Therapeutics, Inc. Filed Acc 0001453687-24-000132
Chief Technology Officer sold 82,368 shares at an average $17.46 ($1,438,038)
- Chief Technology Officer acquired 82,368 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kurtoglu Metin Chief Technology Officer | 2024-11-14 | Option exercise | +25,900 | $1.41 | $36,519 | 76,933 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-14 | Sale | −21,900 | $16.33 | $357,645 | 55,033 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-14 | Sale | −4,000 | $17.06 | $68,256 | 51,033 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-15 | Option exercise | +22,068 | $1.41 | $31,116 | 73,101 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-15 | Sale | −22,068 | $17.20 | $379,497 | 51,033 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-18 | Option exercise | +34,400 | $1.41 | $48,504 | 85,433 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-18 | Sale | −16,672 | $18.19 | $303,212 | 68,761 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-18 | Sale | −17,728 | $18.58 | $329,429 | 51,033 | D |
| Derivatives | |||||||
| Kurtoglu Metin Chief Technology Officer | 2024-11-14 | Option exercise · Stock Option (Right to Buy) | −25,900 | 187,920 | D | ||
| Kurtoglu Metin Chief Technology Officer | 2024-11-15 | Option exercise · Stock Option (Right to Buy) | −22,068 | 165,852 | D | ||
| Kurtoglu Metin Chief Technology Officer | 2024-11-18 | Option exercise · Stock Option (Right to Buy) | −34,400 | 131,452 | D | ||
| Open-market sales · 82,368 sh · avg $17.46 · $1,438,038 | |||||||
Loading xslF345X05/wk-form4_1731976349.xml…